PCN36 COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN RUSSIA
May 1, 2011, 00:00
10.1016/j.jval.2011.02.894
https://www.valueinhealthjournal.com/article/S1098-3015(11)01033-3/fulltext
Title :
PCN36 COST ANALYSIS, SAFETY, AND EFFICACY OF PEMETREXED/CISPLATIN COMPARED WITH BEVACIZUMAB/GEMCITABINE/CISPLATIN IN PATIENTS WITH PREVIOUSLY UNTREATED ADVANCED NON-SQUAMOUS NSCLC IN RUSSIA
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(11)01033-3&doi=10.1016/j.jval.2011.02.894
First page :
A161
Section Title :
Disease-Specific Studies
Open access? :
No
Section Order :
368